IL-27-driven immunoregulatory pathways in T cells
View/ Open
20211109_Thesis_Huiyuan Zhang.pdf (5.909Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Zhang, Huiyuan
Metadata
Show full item recordCitation
Zhang, Huiyuan. 2021. IL-27-driven immunoregulatory pathways in T cells. Doctoral dissertation, Harvard University Graduate School of Arts and Sciences.Abstract
IL-27 is a pleiotropic cytokine that exert immunoregulatory functions through multiple mechanisms, including induction of IL-10 and multiple co-inhibitory receptors on T cells, but the transcriptional network mediating its diverse functions remains unclear. Combining high-resolution temporal RNA profiling with computational algorithms, we predicted 79 transcription factors induced by IL-27 in T cells. We genetically perturbed 24 TFs and generated an experimentally refined regulatory network for Il10. Our study validated 11 known and discovered 5 positive (Cebpb, Fosl2, Tbx21, Hlx, Atf3) and 2 negative (Irf9, Irf8) Il10 regulators. We report two central regulators, Prdm1 and Maf, that cooperatively drive the expression of signature genes induced by IL-27 in Type 1 regulatory T cells, mediate IL-10 expression in other helper T cells and determine the regulatory phenotype of colonic Foxp3+ regulatory T cells. Prdm1/Maf double-knockout mice develop spontaneous colitis, phenocopying the Il10-deficient mice. Our work provides insights into IL-27 driven transcriptional networks and identifies two shared Il10 regulators that orchestrate immunoregulatory programs across T helper cell subsets.In addition, using the IL-27-induced co-inhibitory gene module as a tool, we discovered LILRB4 as a new co-inhibitory receptor for cancer immunotherapy. Lilrb4-deficient mice are better at controlling tumor growth with improved effector T cell functions in the tumor microenvironment. Transferring Lilrb4-deficient Tregs partially recapitulates the tumor growth control observed in Lilrb4-deficient mice, indicating a Treg-cell intrinsic role of LILRB4 in regulating tumor growth. Moreover, we showed that LILRB4 is preferentially expressed by pathogenic Th17 cells compared to non-pathogenic homeostatic Th17 cells. LILRB4 restrains the encephalitogenicity of Th17 cells in experimental autoimmune encephalomyelitis. Our work demonstrates LILRB4 as a co-inhibitory receptor on T cell that has important function in both cancer and autoimmunity.
In summary, our studies provide insights on how IL-27 suppresses autoimmunity and anti-tumor immunity by regulating IL-10 production and expression of known and novel co-inhibitory molecules such as LILRB4 in T cells.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37371124
Collections
- FAS Theses and Dissertations [5815]
Contact administrator regarding this item (to report mistakes or request changes)